A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Mar 2, 2026 to Jun 5, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints revised (8)
    • Site details revised
    • Collaborators shortened, about 4 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.
Trial Details
NCT Number NCT07294235
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions
(from sponsor)		 Overweight or Obesity
Related terms Obesity, Overweight
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov